{"organizations": [], "uuid": "64fe4d60adff4e9e8ef16666538533f12150074f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180523.html", "section_title": "Archive News &amp; Video for Wednesday, 23 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-amneal-signs-licensing-and-supply/brief-amneal-signs-licensing-and-supply-agreement-for-mabxiences-biosimilar-to-roches-avastin-idUSFWN1SU0JE", "country": "US", "domain_rank": 408, "title": "BRIEF-Amneal Signs Licensing And Supply Agreement For mAbxience's Biosimilar To Roche's Avastin", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.366, "site_type": "news", "published": "2018-05-23T19:37:00.000+03:00", "replies_count": 0, "uuid": "64fe4d60adff4e9e8ef16666538533f12150074f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-amneal-signs-licensing-and-supply/brief-amneal-signs-licensing-and-supply-agreement-for-mabxiences-biosimilar-to-roches-avastin-idUSFWN1SU0JE", "ord_in_thread": 0, "title": "BRIEF-Amneal Signs Licensing And Supply Agreement For mAbxience's Biosimilar To Roche's Avastin", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "amneal pharmaceuticals inc", "sentiment": "negative"}, {"name": "roche's avastin", "sentiment": "neutral"}, {"name": "united states", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 23 (Reuters) - Amneal Pharmaceuticals Inc:\n* MABXIENCE AND AMNEAL ENTER INTO AN AGREEMENT FOR BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES\n* MABXIENCE - CO WILL LEAD PRODUCT, CLINICAL DEVELOPMENT AND SUBSEQUENT MANUFACTURE OF BEVACIZUMAB BIOSIMILAR\n* MABXIENCE - UNDER AGREEMENT, AMNEAL WILL GUIDE PRODUCT THROUGH REGULATORY APPROVAL, HAVE EXCLUSIVE COMMERCIALISATION RIGHTS IN U.S. Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-23T19:37:00.000+03:00", "crawled": "2018-05-24T20:34:21.015+03:00", "highlightTitle": ""}